Navigation Links
Precision Therapeutics Enhances Their Straightforward Approach to Personalizing Cancer Care
Date:1/24/2012

PITTSBURGH, Jan. 24, 2012 /PRNewswire/ -- Precision Therapeutics, Inc. has recently expanded their BioSpeciFx® product to include 21 clinically-relevant biomarkers to help physicians with their treatment decisions. This enhances Precision's approach to personalizing cancer care by offering additional molecular markers, including the recently FDA-approved ALK-FISH test. By utilizing BioSpeciFx® results in combination with Precision Therapeutics' ChemoFx® in vitro drug response marker, physicians will receive both molecular and live-cell drug response information about a patient's tumor. Through the integration of these two tests, physicians can create a Comprehensive Tumor Profile, allowing them to more completely define their patient's cancer. In an effort to personalize treatment selection even further, BioSpeciFx® and ChemoFx® tests give physicians the ability to choose from suggested tumor-specific panels or to customize a report for each patient.

"The decision to add new biomarker tests to Precision Therapeutics' Comprehensive Tumor Profile was a direct result of market trends and customer requests," says Sean McDonald, CEO. "Precision is committed to producing multiple products that help physicians make difficult clinical decisions throughout the cancer care continuum. We are in the process of developing several additional tools to help us adhere to our mission of improving the odds of survival and the quality of life for cancer patients."

About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.

Precision's state of the art Comprehensive Tumor Profiling is an integrated straightforward approach combining three core platforms of personalized medicine to capture the total sum of genomic, proteomic and functional information for each patient's cancer through a portfolio of multi-platform tests for cancer treatment in multiple tumor types.

Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. Precision currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. To date, over 77,000 patient specimens have been submitted for ChemoFx® testing using 105 unique chemotherapy treatments and combinations.

For more information, visit www.precisiontherapeutics.com or www.chemofx.com.

 


'/>"/>
SOURCE Precision Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
2. Applied Precision Announces New Products for Life Sciences Microscopy at the 110th American Society for Microbiology Meeting in San Diego, CA, May 23-26th.
3. Precision Bearing Technologies Featured at Atlantic Design & Manufacturing Show
4. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
5. Applied Precisions Mobile Imaging Lab Hits the Road for a Cross-Country Journey
6. Clinical Experts Detail How They Use Varians TrueBeam™ Technology to Improve the Precision and Speed of Cancer Treatments
7. Precision Therapeutics President and CEO Sean McDonald Recognized as a Leading Business Executive and Recipient of 2010 Pacesetters Award
8. Applied Precision Installs a Record Four New DeltaVision OMX Super-Resolution Imaging Systems in Eight Weeks
9. Exempla Saint Joseph Hospital Commences Treating Cancer Patients Using New TrueBeam™ System for High-Precision Image-Guided Radiotherapy and Radiosurgery
10. Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico
11. Applied Precision Scientific Team to Present 3D-SIM Paper at BiOS in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & ... upcoming investor conferences: SeeThru Equity MicroCap Conference   ... New York City , NY When: Tuesday, May ... Conference   Where: Grand Hyatt Hotel, 109 East 42 ...
(Date:5/26/2016)... May 26, 2016   Change Healthcare ... analytics, network solutions and technology-enabled services designed ... entered into a strategic channel partnership with ... software solutions and revenue cycle management services ... and rehabilitation clinics to optimize revenue, operational ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... Mediaplanet to help educate the many who are unaware of the plight of ... aphasia will run within the “Stroke Awareness” campaign. , The link between stroke ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year Standard ... Allison Outerbridge is this year’s Life University winner of a $2,500 ... university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last quarter at ...
(Date:5/26/2016)... ... , ... Despite last week’s media reports hinting at a June rate hike ... March 2017 for an interest rate increase, according to Rajeev Dhawan of the Economic ... Federal Open Market Committee (FOMC) dot charts are of interest to the press for ...
Breaking Medicine News(10 mins):